• Trendlyne logo
  • Markets
  • Alerts
  • F&O
  • MF
  • Reports
  • Screeners
  • Subscribe
  • Superstars
  • Portfolio
  • Watchlist
  • Insider Trades
  • Results
  • Data Downloader
  • Events Calendar
  • What's New
  • Explore
  • FAQs
  • Widgets
More
    Search stocks
    IND USA
    IND
    IND
    IND
    USA
    • Stocks
    • Futures & Options
    • Mutual Funds
    • News
    • Fundamentals
    • Reports
    • Corporate Actions
    • Alerts
    • Shareholding
    logo
    Alembic Pharmaceuticals Ltd.
    19 Aug 2025
    946.50
    -0.07%
    Alembic Pharma shares rise 2% on pulmonary hypertension drug approval
    Business Standard
    Alembic Pharma shares rose 2.3 per cent on Tuesday, after the company received US Food & Drug Administration (USFDA) final approval for its Abbreviated New Drug Application (ANDA) Macitentan Tablets
    Copy LinkShare onShare on Share on Share on
    Alembic Pharmaceuticals Ltd. is trading below all available SMAs
    logo
    Marksans Pharma Ltd.
    18 Aug 2025
    172.93
    -0.73%
    Marksans Pharma gains 3% on UK MHRA approval for subsidiary; details here
    Business Standard
    The upward movement in Marksans Pharma's share price came after the company announced that its wholly owned subsidiary, Relonchem in the UK, had received marketing authorisation for its products
    Copy LinkShare onShare on Share on Share on
    Marksans Pharma Ltd. has lost -35.49% in the last 1 Year
    logo
    Alembic Ltd.
    18 Aug 2025
    103.16
    -0.80%
    Alembic gets USFDA nod for generic drug for skin condition
    Business Line
    The company has received final approval from the US Food & Drug Administration for its abbreviated new drug application for Tretinoin Cream USP, the drug maker said in a statement
    Copy LinkShare onShare on Share on Share on
    Alembic Ltd. has lost -33.65% in the last 1 Year
    logo
    Alembic Pharmaceuticals Ltd.
    18 Aug 2025
    946.50
    -0.07%
    Alembic gets USFDA's approval for generic acne drug Tretinoin Cream
    Business Standard
    Alembic Pharmaceuticals on Monday said it has received approval from the US health regulator to market a generic medication to treat acne vulgaris in the US market. The company has received final approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Tretinoin Cream USP (0.025 per cent), the drug maker said in a statement. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Retin-A Cream, 0.025 pr cent, of Bausch Health US, LLC, it added. Tretinoin cream is indicated for topical application in the treatment of acne vulgaris. According to IQVIA, Tretinoin cream USP, 0.025 per cent, has an estimated market size of USD 94 million for the twelve months ending June 2025. Shares of the company were trading 1.03 per cent up at Rs 968.10 apiece on BSE.
    Copy LinkShare onShare on Share on Share on
    Alembic Pharmaceutic.. has an average target of 1001.00 from 4 brokers.
    logo
    Aurobindo Pharma Ltd.
    17 Aug 2025
    1094.40
    -1.33%
    Aurobindo Pharma expects China plant to break even at EBITDA level this year
    Business Line
    "This facility with an initial capacity of 2 bn units plus is ramping up as expected and will begin contributing to revenue in the coming quarters and is expected to break even at the EBITDA level by Q3 FY26"
    Copy LinkShare onShare on Share on Share on
    Promoters pledged 0.16% of shares in last quarter. Total pledge stands at 17.08% of promoter holdings
    Aurobindo Pharma expects China plant to break even at Ebitda level in FY26
    Business Standard | 17 Aug 2025
    logo
    Glenmark Pharmaceuticals Ltd.
    15 Aug 2025
    Dividend
    2132.50
    0.23%
    Glenmark Pharmaceuticals Q1 PAT down 86% dragged by US litigation settlement provision
    Business Line
    Consolidated total revenue from operations in Q1FY26 stood at 3,264.44 crore as against 3,244.19 crore in the same period a year ago.
    Copy LinkShare onShare on Share on Share on
    Glenmark Pharmaceuticals Ltd. has gained 30.06% in the last 3 Months
    Glenmark Pharmaceuticals Q1 Results: Profit Plunges 86%
    NDTV Profit | 14 Aug 2025 1 more
    Glenmark Pharma Q1FY26 profit slumps 86% to 47 cr, revenue down 5%
    Business Standard | 14 Aug 2025
    logo
    Strides Pharma Science Ltd.
    14 Aug 2025
    909.75
    -0.14%
    Strides towards Naya Bharat
    Business Line
    Copy LinkShare onShare on Share on Share on
    Strides Pharma Science Ltd. has gained 49.53% in the last 6 Months
    logo
    Anthem Biosciences Ltd.
    14 Aug 2025
    833.50
    1.53%
    Recently listed biotech stock surges 44% against issue price; time to sell?
    Business Standard
    Shares of Anthem Biosciences surged 9 per cent to 820 on the BSE in Thursday's intra-day trade amid heavy volumes after reporting a strong earnings for the quarter ended June 2025.
    Copy LinkShare onShare on Share on Share on
    Anthem Biosciences Ltd. has gained 46.23% in the last 6 Months
    logo
    Shilpa Medicare Ltd.
    14 Aug 2025
    Dividend
    827.60
    -1.08%
    Shilpa Medicare share jumps 4% on 1:1 bonus issue; check record date here
    Business Standard
    Shilpa Medicare shares rose after the company announced a 1:1 bonus issue, with the Board approving the proposal in its meeting on August 13, 2025.
    Copy LinkShare onShare on Share on Share on
    Shilpa Medicare Ltd. is trading below its 30 day SMA of 852.1
    Shilpa Medicare Announces 1:1 Bonus Issue After Q1 Profit Triples Check Record Date
    NDTV Profit | 13 Aug 2025, 05:02PM
    logo
    Lupin Ltd.
    13 Aug 2025, 11:51PM
    2043.40
    2.79%
    Mixed Q1 results for top drug firms amid price erosion, tariff threat
    Business Standard
    Fresh launches boosted growth for players like Lupin, Torrent
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors increased from 979 to 987 in Jun 2025 qtr.
    more
    loading
    Logo Trendlyne

    Stay ahead of the market

    Company

    PrivacyDisclaimerTerms of Use Contact Us

    Resources

    Blog FAQsStock Market Widgets

    Copyright © 2025 Giskard Datatech Pvt Ltd